Eurazeo: invests in medtech Germitec
(CercleFinance.com) - Eurazeo announces that its Nov Santé Actions Non Cotées fund, dedicated to European healthcare sectors and launched at the initiative of France Assureurs and Caisse des Dépôts, has finalized its third growth equity investment in medtech Germitec.
Nov Santé Actions Non Cotées is acting as lead investor in a E29m Series B alongside existing shareholders including Kurma Partners (Eurazeo's Venture Santé subsidiary), Financière Arbevel, Turenne Capital and the founding family.
Specialising in high-level disinfection of ultrasound probes, Germitec is already present in over 40 countries, and aims to establish itself in new markets such as the US, where it has obtained FDA certification for its flagship product, Chronos.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Nov Santé Actions Non Cotées is acting as lead investor in a E29m Series B alongside existing shareholders including Kurma Partners (Eurazeo's Venture Santé subsidiary), Financière Arbevel, Turenne Capital and the founding family.
Specialising in high-level disinfection of ultrasound probes, Germitec is already present in over 40 countries, and aims to establish itself in new markets such as the US, where it has obtained FDA certification for its flagship product, Chronos.
Copyright (c) 2025 CercleFinance.com. All rights reserved.